BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burt T, MacLeod D, Lee K, Santoro A, DeMasi DK, Hawk T, Feinglos M, Rowland M, Noveck RJ. Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans. Clin Transl Sci 2017;10:351-9. [PMID: 28689370 DOI: 10.1111/cts.12477] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen D, Qi EY. Innovative highlights of clinical drug trial design. Transl Res 2020;224:71-7. [PMID: 32504825 DOI: 10.1016/j.trsl.2020.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Burt T, Vuong LT, Baker E, Young GC, McCartt AD, Bergstrom M, Sugiyama Y, Combes R. Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development. Altern Lab Anim 2018;46:335-46. [PMID: 30657329 DOI: 10.1177/026119291804600603] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
3 Bai H, Lu J, Cheng X, Liu L, Zhang W, Wei Y, Wang Y, Liu J, Ding J, Yu Q, Zhang Y, Chen G, Fan Y, Wang X. Development and validation of an ultrasensitive LC-MS/MS method for the quantification of cetagliptin in human plasma and its application in a microdose clinical trial. Biomed Chromatogr 2021;35:e4994. [PMID: 32986878 DOI: 10.1002/bmc.4994] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M, Sugiyama Y. Phase 0/microdosing approaches: time for mainstream application in drug development? Nat Rev Drug Discov 2020;19:801-18. [PMID: 32901140 DOI: 10.1038/s41573-020-0080-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]